PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33102759-10	2020	However, baseline serum FGF19 and ANG2 levels were significantly associated with treatment response to lenvatinib.	lenvatinib	103-113	angiopoietin 2	Homo sapiens	34-38	
33102759-11	2020	All (9/9) patients with low baseline ANG2 and FGF19 levels who received lenvatinib achieved OR.	lenvatinib	72-82	angiopoietin 2	Homo sapiens	37-41	
28237867-8	2017	For lenvatinib-treated patients, interaction-term analyses revealed that low baseline Ang2 level was predictive of tumour shrinkage (Pinteraction = 0.016) and PFS (Pinteraction = 0.018).	lenvatinib	4-14	angiopoietin 2	Homo sapiens	86-90	
28237867-13	2017	Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients, indicating that Ang2 may be predictive of lenvatinib sensitivity.	lenvatinib	53-63	angiopoietin 2	Homo sapiens	9-13	
28237867-13	2017	Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients, indicating that Ang2 may be predictive of lenvatinib sensitivity.	lenvatinib	53-63	angiopoietin 2	Homo sapiens	98-102	
28237867-13	2017	Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients, indicating that Ang2 may be predictive of lenvatinib sensitivity.	lenvatinib	124-134	angiopoietin 2	Homo sapiens	9-13	
28237867-13	2017	Baseline Ang2 was predictive of PFS in a subgroup of lenvatinib-treated patients, indicating that Ang2 may be predictive of lenvatinib sensitivity.	lenvatinib	124-134	angiopoietin 2	Homo sapiens	98-102	
35530647-1	2022	BACKGROUND/AIM: The purpose of this study was to investigate the relationships between the plasma concentration of Lenvatinib (C0), the levels of angiopoietin (Ang)-1 and Ang-2, and clinical responses to lenvatinib therapy in patients with thyroid cancer.	lenvatinib	115-125	angiopoietin 2	Homo sapiens	171-176	
35530647-7	2022	CONCLUSION: The decrease in Ang-2 at 1 month of treatment from baseline may be important as a biomarker of the inhibitory effect of lenvatinib on angiogenesis.	lenvatinib	132-142	angiopoietin 2	Homo sapiens	28-33	
31991869-0	2020	Early Changes in Circulating FGF19 and Ang-2 Levels as Possible Predictive Biomarkers of Clinical Response to Lenvatinib Therapy in Hepatocellular Carcinoma.	lenvatinib	110-120	angiopoietin 2	Homo sapiens	39-44	
31991869-5	2020	Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 vs. 0.810, respectively, p = 0.0002).	lenvatinib	106-116	angiopoietin 2	Homo sapiens	70-75	
31991869-5	2020	Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 vs. 0.810, respectively, p = 0.0002).	lenvatinib	106-116	angiopoietin 2	Homo sapiens	77-84	
31991869-5	2020	Results: Significantly increased FGF19 (FGF19-i) levels and decreased Ang-2 (Ang-2-d) levels were seen in Lenvatinib responders as compared to non-responders (ratio of FGF19 level at 4 weeks/baseline in responders vs. non-responders: 2.09 vs. 1.32, respectively, p = 0.0004; ratio of Ang-2 level at four weeks/baseline: 0.584 vs. 0.810, respectively, p = 0.0002).	lenvatinib	106-116	angiopoietin 2	Homo sapiens	77-82	
31991869-7	2020	In multivariate analysis, the combination of serum FGF19-i and Ang-2-d was the most independent predictive factor for Lenvatinib response (Odds ratio, 9.143; p = 0.0012).	lenvatinib	118-128	angiopoietin 2	Homo sapiens	63-70	
31991869-9	2020	Early changes in circulating FGF19 and Ang-2 levels might be useful for predicting clinical response and progression-free survival in HCC patients on Lenvatinib therapy.	lenvatinib	150-160	angiopoietin 2	Homo sapiens	39-44